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ABSTRACT
Background. Historically, blue dyes, 99Tc or a combina-
tion of the two tracers have been used for sentinel lymph
node (SLN) mapping in cervical and endometrial cancer
patients. Indocyanine green (ICG), as a tracer, has been
recently introduced in this setting. Our goal was to assess
the differences in overall and bilateral detection rates as
well as in false-negative rates among the different tracers.
Methods. The electronic databases PubMed, MEDLINE,
and Scopus were searched in January 2016 by searching
the terms ‘‘sentinel lymph node’’ and ‘‘dye’’ and ‘‘indo-
cyanine green,’’ and ‘‘cervical cancer’’ or ‘‘endometrial
cancer.’’ Series comparing different tracers injected
intracervically and reporting the detection rate and/or SLN
false-negative rate were selected.
Results. Forty-five studies were retrieved. Six studies
including 538 patients met selection criteria. Compared
with blue dyes, ICG SLN mapping had higher overall (odds
ratio [OR] 0.27; 95 % confidence interval [CI] 0.15–0.50;
p\ 0.0001) and bilateral detection rates (OR 0.27; 95 %
CI 0.19–0.40; p\ 0.00001). No differences were found
between ICG and 99TC, although these results are based on
data of a single series. No differences in overall and
bilateral detection rates were found between ICG and the
combination of blue dyes and 99TC. The pooled analysis of
false-negative rates data showed no difference in false-
negative rates between tracers.
Conclusions. In cervical and endometrial cancer, ICG
SLN mapping seems to be equivalent to the combination of
blue dyes and 99TC in terms of overall and bilateral
detection rates. Its safety profile and ease of use may favor
its employment respect to conventional tracers.
Although sentinel lymph node (SLN) mapping has been
investigated in gynecologic oncology for over a decade, it
has gained widespread diffusion only recently.1 Since
2014, SLN mapping has been recognized by NCCN
guidelines as an appropriate surgical lymph node assess-
ment in patients with cervical and endometrial cancer.2,3
When substituting a lymphadenectomy with a SLN map-
ping, an algorithm that includes the removal of any
suspicious lymph node and a side-specific lymphadenec-
tomy on every non-mapping hemipelvis in addition to the
SLN biopsy is recommended.4,5 Because the uterus is a
midline structure, its lymphatic flow involves the bilateral
pelvic lymph nodes. Hence, the most successful SLN
mapping is the one that detects at least a SLN on each
hemipelvis. From an oncological perspective, it is crucial
that a SLN mapping technique is characterized by low
false-negative rates to minimize the risk to undertreat
patients.
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Historically, SLN mapping has been performed with
99Technetium radiocolloid (99Tc) alone or in combination
with blue dyes. However, these tracers have some side
effects. Blue dyes cause discoloration of the skin and urine,
a decrease in pulse oximetry readings and occasionally
severe allergic reactions. Mapping with 99TC is logistically
complicated because of the coordination required between
the injection in a controlled environment, the imaging
acquisition and the surgery, making this technique more
time-consuming and expensive.
Indocyanine green (ICG) is an intravascular confined
fluorescent dye that has been used in ophthalmology to
visualize the retinal and choroid vascularization for more
than 40 years.6 Recently, ICG has been used for SLN
detection in various tumors with promising. At present, it is
still unclear how ICG performs as a tracer for SLN map-
ping in cervical and endometrial cancer compared with
other conventional tracers.
The purpose of this meta-analysis was to compare the
efficacy of ICG versus other conventional tracers (99Tc,
blue dyes or a combination of the two) in terms of overall
and bilateral detection rates and false negative rates, in
cervical and endometrial cancer patients undergoing SLN
mapping.
METHODS
Data Identification and Selection
This meta-analysis was performed following the Pre-
ferred Reporting Items for Systematic reviews and Meta-
Analyses (PRISMA) statement and included all studies
without any restriction on publication year. On January
2016, a systematic literature search was performed. Data
were identified using the electronic databases PubMed,
MEDLINE, and Scopus by searching the terms ‘‘sentinel
lymph node’’ and ‘‘dye’’ and ‘‘indocyanine green,’’ and
‘‘cervical cancer’’ or ‘‘endometrial cancer.’’ All English-
language original reports evaluating the efficacy of SLN
mapping with ICG or other conventional dyes (99Tc, blue
dyes or a combination of these two) in patients affected by
cervical or endometrial cancer were considered for inclu-
sion. Studies reporting laparotomy, laparoscopic, or robotic
surgery for SLN biopsy were all assessed for inclusion. The
reference list of original reports and reviews already pub-
lished also were analyzed to identify other potential studies.
In endometrial cancer, intracervical, hysteroscopic, and
subserosal tracer injections for SLN mapping have been
described. However, only series in which the tracer for the
SLN mapping was injected intracervically were selected
due to the overwhelming diffusion of this procedure and its
proven correlation with higher detection rates.7–13
Only studies comparing the efficacy of SLN mapping
with ICG versus blue-dyes, 99Tc or a combination of the
two were included in the meta-analysis. Review articles,
case reports, video articles, and letters were excluded. Two
independent reviewers (IR and MLG) identified and
selected the studies based on inclusion and exclusion cri-
teria. Divergent opinions were resolved by consultation
between the reviewers with the involvement of a third
author (AP).
For each study included in the meta-analysis, the fol-
lowing data were recorded: first author’s information,
publication year, study design, sample size, type of cancer,
type of surgery (robotic, laparoscopy or laparotomy), SLN
detection rate, and false-negative rate.
Endpoints
The primary endpoints were the overall and bilateral
detection rates of the different mapping tracers (ICG vs.
conventional dyes), expressed in terms of risk failure in
detecting at least one SLN and at least one SLN per
hemipelvis respectively. We assessed overall and bilateral
detection rates of different SLN mapping tracers compar-
ing ICG versus blue dyes only, ICG versus 99Tc only, and
ICG versus the combination of blue dyes and 99Tc.
The secondary endpoint was the SLN false-negative rate
using different mapping tracers. We assessed the SLN
false-negative rate comparing ICG versus blue dyes only,
ICG versus 99Tc only, and ICG versus the combination of
blue dyes and 99Tc. For this purpose, only studies reporting
SLN false-negative rates on fully staged patients were
considered. Studies reporting SLN false-negative rates
based on patients who were not subjected to both SLN
biopsy and complete lymphadenectomy were excluded.
Statistical Analysis
Risk failure of overall and bilateral detection of SLNs
using ICG versus the other conventional tracers was
stratified by studies and the pooled odds ratio (OR) or risk
ratio (RR) were calculated using a fixed- or a random-
effects model. A v2 test for heterogeneity among propor-
tions was performed to assess the presence of statistical
heterogeneity between studies. A fixed-effects model was
used if statistical heterogeneity was not significant (I2 value
B50 %); differently, a random-effects model was adopted.
Graphical representation of each study and pooled analysis
was displayed by forest plots. The weight that each study
provides in the meta-analysis was graphically reported as a
square of different size. Confidence intervals (CIs) for each
study were symbolized as a horizontal line passing through
the square. The pooled OR or RR were represented as a
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lozenge in the forest plot and its size corresponded to the
95 % CI of the OR. A p value B0.05 was considered sig-
nificant. Statistical analysis was performed using Review
Manager 5.3 (http://www.cochrane.org).
RESULTS
Overall, 45 studies were retrieved through the literature
search. Among these, 13 (28.9 %) studies were removed as
duplicates. Twenty-four (53.3 %) were excluded after title
and abstract evaluation, because two (4.4 %) studies were
not English-language original reports, three (6.7 %) studies
regarded nongynecologic cancers, one (2.2 %) study was
performed on animals, three (6.7 %) reports were reviews,
three (6.7 %) were case reports, one (2.2 %) was a video
article, one (2.2 %) was a letter, and ten (22.2 %) studies
did not compare ICG with other conventional tracers. Two
(4.4 %) further studies were excluded successively after
full-text evaluation. In the first a nonintracervical tracer
injection was used, whereas in the second a population that
was later reported more extensively was presented.14–16 Six
studies (13.4 %) remained for comparison at the end of the
selection process. The PRISMA flow chart summarizing
the process of evidence acquisition is presented in Fig. 1.
The flow chart maps out the number of studies identified,
screened, included, and excluded as well as the reasons for
exclusions.
Overall, 538 patients were included. A total of 173
(32.2 %) patients underwent laparoscopic SLN mapping;
318 (59.1 %) of the patients underwent a robotic SLN
mapping and 48 (8.9 %) patients underwent a SLN map-
ping via laparotomy.
In two series, a combination of tracers was used in the
same patient; however, detection rates were reported sep-
arately for each tracer, thus allowing extrapolation of the
data for each tracer or a combination thereof in each case.
In one series, 100 (18.6 %) patients underwent SLN with
all the three tracers.12 In another series, 35 (6.5 %) patients
underwent SLN mapping with both ICG and blue dye.17 In
the other four series, different groups were mapped with
different tracers. In these series, SLN mapping was per-
formed as follows: 165 (30.7 %) patients underwent ICG
SLN mapping, whereas 113 (21 %) patients underwent
SLN mapping with a combination of blue-dyes and 99TC
and 131 (24.3 %) patients underwent SLN mapping with
blue dyes only.10,13,16,18 From one of the selected series
comparing SLN mapping with ICG versus blue-dyes, only
data on bilateral and not on overall detection rates could be
extrapolated.18
All six studies included in the meta-analysis reported the
number of false-negative cases, but in two studies, data on
false-negative rates per tracer used could not be extrapo-
lated.12,18 Consequently, these two studies where excluded
from the false-negative rate analysis. Furthermore, one
study reported the false-negative rate on a SLN algorithm
and therefore was excluded from the analysis as well.10
The characteristics of the selected studies are listed in
Table 1.
Overall and Bilateral Detection Rates
ICG Versus Blue-Dyes When comparing ICG with blue
dyes for SLN mapping, the pooled analysis data showed a
significant increase in overall detection rate for ICG SLN
Records identified through electronic
databases searching for ”sentinel lymph node”
and  “dye” and ”green indocyanine” , and





Records excluded after title and abstract
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FIG. 1 PRISMA flow diagram
on the meta-analysis process
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mapping (OR 0.27; 95 % CI 0.15–0.50; p\ 0.0001, fixed-
effect model; Fig. 2a). For bilateral detection rates, the
pooled analysis data showed a significant increase for ICG
SLN mapping (OR 0.27; 95 % CI 0.19–0.40; p\ 0.00001,
fixed-effect model; Fig. 2b).
ICG Versus 99Tc When comparing ICG with 99Tc for
SLN mapping, the pooled analysis data showed no
differences in overall detection rates between the two
methods (OR 1.08; 95 % CI 0.52–2.26; p = 0.83, fixed-
effect model; Fig. 3a). For bilateral detection rates, the
pooled analysis data showed no difference between the two
methods (OR 1.21; 95 % CI 0.80–1.81; p = 0.36, fixed-
effect model; Fig. 3b).
ICG Versus Blue-Dyes and 99Tc Combined When
comparing ICG with 99Tc for SLN mapping, the pooled
analysis data showed no differences in overall detection rates
between the two methods (OR 0.96; 95 % CI 0.45–2.02;
p = 0.91, fixed-effect model; Fig. 4a). For bilateral detection
rates, the pooled analysis data showed a nonsignificant
increase for ICG SLN mapping (OR 0.37; 95 % CI 0.07–2.12;
p = 0.27 random-effect model; Fig. 4b).
False-Negative Rates When comparing ICG with
blue-dyes for SLN mapping, the pooled analysis data
showed no difference in false-negative rates between the
two groups (OR 0.26; 95 % CI 0.02–3.06; p = 0.28, fixed-
effect model; Fig. 2c).16,17
Study comparing ICG versus blue-dyes ? 99Tc reported
no cases of false-negative SLNs in both groups.13,16 When
comparing ICG versus 99Tc alone, it is not possible to
establish the number of false-negative cases per each
group, because the only study comparing these two tracers
a Overall Detection rate°
b Bilateral Detection rate°
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FIG. 2 SLN mapping: ICG versus blue dyes. a Overall detection rate. b Bilateral detection rate. c False-negative SLN mapping rates
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did not specify the type of tracer per reported false-nega-
tive SLN.12
DISCUSSION
Different tracers for SLN mapping have been used in
cervical and endometrial cancer. The most commonly used
are blue dyes and 99TC, with detection rates that range
between 70 and 100 %; however, these data mainly relate
to overall detection rates, whereas bilateral detection rates
are significantly lower.19,20 It has been demonstrated that
the combination of blue dyes and 99Tc yields higher
detection rates than any of the two tracers alone, with
values that are as high as 90 %.21,22
Recently, encouraging results with the use of ICG as a
tracer for SLN mapping have been reported.8,9,23 However,
whether ICG is superior to the other conventional tracers
alone or in combination for the SLN mapping in uterine
malignancies is still an unanswered question.
In the present study, we performed a meta-analysis on
series evaluating overall and bilateral detection rates for
SLN mapping in uterine cancer using different tracers. We
observed that ICG SLN mapping increases both overall and
bilateral detection rates by 27 % compared with blue dyes.
No differences were recorded in overall and bilateral
detection rates between ICG and 99TC; however, these
results are based on data from a single series. When
comparing ICG with the combination of blue dyes and
99Tc, no differences in overall detection rate between the
two groups were recorded. Although nonsignificant, an
improvement in bilateral detection rate for ICG was noted.
As far as false-negative rates, no differences were recorded
between ICG and other conventional tracers.
When adopting the SLN mapping algorithms for cervi-
cal and endometrial cancer proposed by the MSKCC,
higher overall and bilateral detection rates will lead to a
lower number of side-specific lymphadenectomies on
nonmapping hemipelvises.4,5 This may ultimately result in
a reduction in lymphadenectomy-related surgical morbid-
ity, which has been reported to be as high as 20 %.24
Cervical and endometrial cancer patients without lymph
nodal metastases often do not undergo any adjuvant treat-
ment. In this setting, low to virtually absent false-negative
rates are crucial for oncological safety.25 Furthermore, it
has been demonstrated that the highest NPV for the SLN
mapping in early stage cervical cancer is reached in
patients with bilateral negative SLN mapping.26
In this view, our results are clinically relevant, because
they may help physicians to choose which SLN mapping
strategy to adopt and to counsel patients with regards to the
oncological safety of the procedure and their risk of still
undergoing a full lymphadenectomy despite undergoing
SLN mapping for their uterine malignancies.
Our results may be accompanied by some limitations.
First, surgical approach in the selected studies differed
from a laparoscopic, robotically assisted laparotomy. This
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FIG. 3 SLN mapping detection rates: ICG versus 99Tc. a Overall detection rate. b Bilateral detection rate
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may have influenced the detection rates, because the plat-
forms for the ICG-NIR technology are different based on
surgical approach. However, the high detection rates
recorded in every series suggest that the tracer, rather than
the platform, is responsible for the results. Second, both
cervical and endometrial cancer patients are included.
Although the neoplastic involvement of the cervix may
affect the lymphatic uptake of the tracer in patients with
cervical cancer, leading to differences in SLN mapping
among these and endometrial cancer patients, series
including both groups of patients have been published.
There does not seem to be a substantial difference among
the two scenarios. Additionally, the uterus has a complex
lymphatic drainage system based on three anatomical
Study or Subgroup Total Total WeightEvents
Combination odds Ratio Odds Ratio
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TABLE 1 Characteristics of the studies included in the meta-analysis
Author
(ref.)
















Retrospective 35 Endometrial Robotic ICG (35) ? BD (35) 2 ml (ICG), 4 ml (BD) n.a. 22.6 (±10.9)
Sinno
et al.10
Retrospective 71 Endometrial Robotic ICG (38); BD (33) 4 ml (ICG), 4 ml (BD) 2.23 (0–9) n.a.
Tanner
et al.18
Retrospective 111 Endometrial Robotic ICG (57); BD (54) 4 ml (ICG), 4 ml (BD) 2.9 (0–12) n.a.
How
et al.12a
Prospective 100 Endometrial Robotic ICG (100) ? TC
(100) ? BD (100)
0.4 ml (ICG), 0.4 ml




Retrospective 58 Cervical Laparoscopy ICG (22); TC ? BD
(36)
8–10 ml (ICG), 120 mBq












ICG (48); BD (38);
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BD blue dye, ICG indocyanine green, TC 99Technetium, n.a. not available
a All the patients in the series underwent SLN mapping with the same tracers but overall and bilateral detection rates were reported separately for
each tracer
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pathways: one (the most commonly involved in the lym-
phatic spread of the disease) draining to the iliac nodes, one
draining the fundus mainly via the gonadal vessels to the
high paraaortic area, and one draining to the inguinal
lymph nodes through the round ligament.27 The cervical
injection of the tracer therefore may not always represent
the best choice for proper mapping in patients with
endometrial cancer, especially if this is located in the
fundal area. Therefore, some authors recommend a hys-
teroscopic intratumoral injection of the tracer.28 Although a
matter of debate, because of the documented marginal risk
of isolated para-aortic lymph nodes and because of its
‘‘user friendliness,’’ the cervix remains the preferred and
most commonly adopted site of injection of the tracer for
SLN mapping in endometrial cancer.29
CONCLUSIONS
This meta-analysis demonstrated that ICG SLN seems to
be equivalent to the combination of blue dyes and 99TC
with in terms of overall and bilateral detection rates in
uterine malignancies. The good toxicity profile and ease of
use of ICG, which does not require the injection in a
controlled environment and an image acquisition before
surgery, along with the availability of integrated platforms
for minimally invasive approaches that make the SLN
mapping easy and intuitive, may favor the choice of this
tracer over the combination of blue dyes and 99Tc.
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